title: Predictors and impacts of hospital readmissions following liver transplantation.
abstract: While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver transplantation can be associated with adverse outcomes, increased cost, and resource utilization. Our aim was to define the incidence and reasons for hospital readmission after liver transplant and the impact of readmissions on patient outcomes. We retrospectively analyzed 30- and 90-day readmission rates and indications in patients who underwent liver transplant at a large-volume transplant center over a 3-year period. Four hundred seventy-nine adult patients underwent their first liver transplant during the study period. The 30-day readmission rate was 29.6%. Recipient and donor age, etiology of liver disease, biological Model for End-Stage Liver Disease score, and cold ischemia time were similar between patients who were readmitted within 30 days and those who were not readmitted. Readmissions occurred in 25% of patients who were hospitalized prior to liver transplant compared to 30% who were admitted for liver transplant. The most common indications for readmission were infection, severe abdominal pain, and biliary complications. Early discharge from hospital (fewer than 7 days after liver transplant), was not associated with readmission; however, a prolonged hospital stay after liver transplant was associated with an increased risk of readmission (p = 0.04). In conclusion, patients who undergo liver transplant have a high rate of readmission. In our cohort, readmissions were unrelated to pre-existing recipient or donor factors, but were associated with a longer hospital stay after liver transplant.
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Yataco
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Alissa
authors.initials: A
authors.lastname: Cowell
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Waseem
authors.initials: W
authors.lastname: David
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Keaveny
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: C Burcin
authors.initials: CB
authors.lastname: Taner
authors.affiliation: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: Tushar
authors.initials: T
authors.lastname: Patel
mesh_terms: D000328:Adult; D000368:Aged; D016208:Databases, Factual; D058625:End Stage Liver Disease / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D005260:Female; D005431:Florida / Q000453:epidemiology; D061847:Hospitals, High-Volume; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010351:Patient Discharge; D010359:Patient Readmission; D011183:Postoperative Complications / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult